en.Wedoany.com Reported - VERAXA Biotech AG announced the completion of its business combination with Voyager Acquisition Corp., becoming an innovative biopharmaceutical company listed on Nasdaq, focused on developing next-generation bispecific T-cell engagers and antibody-drug conjugates.
Under the closing agreement, VERAXA Biotech AG merged with Voyager and was consolidated into VERAXA Biotech Holding AG, which was renamed VERAXA Biotech AG. The company's shares will trade under the ticker symbol "VRXA" and warrants under "VRXAW" on the Nasdaq Capital Market starting June 11, 2026. Voyager shareholders approved the transaction on March 12, 2026, while VERAXA shareholders approved it on February 27, 2026.
To advance its pipeline of drug candidates, VERAXA completed a senior secured note financing totaling $27.5 million in principal and signed a stock purchase agreement of up to $50 million. The proceeds from the financing will be used to advance the BiTAC-TCE and BiTAC-ADC programs into clinical development. VERAXA's core technology platform, BiTAC, enables the creation of conditionally activated "AND-gate" therapeutic strategies, precisely targeting cancer cells through dual antigens while preserving healthy cells. This platform also contributes value to complementary fields such as radioimmunoconjugates and antibody-oligonucleotide conjugates.
Preliminary data from VERAXA's most advanced BiTAC program were presented at the 2026 American Association for Cancer Research Annual Meeting. The data showed that the BiTAC-TCE candidate attacks cancer cells expressing both target molecules in vitro and in vivo while sparing cells expressing only one target, demonstrating improved safety and comparable efficacy compared to more traditional TCEs. Dr. Christoph Antz, CEO of VERAXA, stated that the completion of the business combination allows the company to focus on unlocking the potential of the BiTAC platform in cancer therapies.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
